20 results on '"Almquist D"'
Search Results
2. EVOLVE: Evaluating the Safety of De-escalated Head and Neck Irradiation in HPV Positive Oropharynx Cancer in Non/Minimal Smokers.
- Author
-
Blanchard, M.J., primary, Terrell, A., additional, Vegunta, R., additional, Powell, S., additional, Nowak, R.K., additional, Almquist, D., additional, Schmidt, A., additional, Bloch, B., additional, Shafique, K., additional, Geeraerts, L., additional, Nurkic, S.R.W., additional, Jensen, A.W., additional, Ellison, C., additional, and Spanos, W., additional
- Published
- 2022
- Full Text
- View/download PDF
3. The Female of Oxybleptes meridionalis (Coleoptera: Staphylinidae: Staphylininae) and Range Extension for Oxybleptes
- Author
-
Frank, J. H., Foltz, J. L., and Almquist, D. T.
- Published
- 2005
4. Lissohypnus fullertoni Frank and Kelly 2014, new species
- Author
-
Frank, J. H., Kelly, S. L., and Almquist, D. T.
- Subjects
Coleoptera ,Insecta ,Arthropoda ,Lissohypnus fullertoni ,Animalia ,Biodiversity ,Staphylinidae ,Taxonomy ,Lissohypnus - Abstract
Lissohypnus fullertoni Frank and Kelly, new species. Figures 2, 2a, 2b, 2c, 2d In March 2014, SLK sent an unidentified xantholinine specimen suspected to be Neohypnus to JHF for identification. It proved to be a male Lissohypnus, but was not L. texanus. For further clarification of its systematic position especially in relation to the genera Xantholinus and Neohypnus, see Newton et al. (2001). Against the possibility that the specimen belongs to a West Indian species, JHF checked the key to West Indian ‘ Xantholinus ’ provided by Blackwelder (1943); the specimen keyed out to X. oakleyi Blackwelder, but did not at all match the description of the diminutive (2.5-4.5 mm) adults of that species known from Hispaniola and Puerto Rico. Against the possibility that the specimen belongs to a Mexican species, the original descriptions of all the four species of Lissohypnus reported in Mexico by Navarrete-Heredia et al. (2002) were read and found not to match the specimen. Although we have seen only this one specimen, we think it is distinct from the single U.S. species known to belong to Lissohypnus, and it is not a West Indian species known to Blackwelder (1943), nor a Mexican species known to Navarrete-Heredia et al. (2002) so we here describe it as a new species. Description. Head piceous, pronotum castaneous, elytra, abdomen, maxillary palpi and legs paler to rufo-testaceous on apical 2/3 of elytra and first two visible segments of abdomen and 2 nd and 3 rd pairs of legs, antennae castaneous with antennomeres IV-X and base of XI infuscate. Head longer than wide (index 1.20), only slightly dilated posteriorly, posterior angles rounded; frontal groves moderately distinct and long, slightly curved medially in posterior half, ocular grooves absent; eyes small and almost flat, tempora much longer than length of eyes seen from above (index 2.2), punctation of head coarse and moderately dense laterally, punctures becoming sparser medially and gradually disappearing anteriorly; without impunctate median strip on posterior half of head; surface of head glossy, without microsculpture; gula short and narrow, sutures behind it contiguous. Antennae geniculate with first antennomere (scape) long and stout, widened toward apex, antennomeres II and III elongate, III slightly longer than II, outer antennomeres strongly transverse, apical antennomere about as long as preceding two combined, and acorn-shaped. Pronotum longer than wide (index 1.3), slightly narrowed posteriorly; dorsal rows each with 11-12 punctures; lateral rows each with 6 punctures; surface of pronotum without microsculpture. Elytra moderately long, at suture a little (index 0.80); at sides feebly (index 0.97) shorter than length of pronotum at midline; punctation rather coarse and moderately dense, irregular; surface without microsculpture. Macropterous. Abdomen with punctation fine and moderately dense, gradually becoming sparser medially; pubescence pale, moderately dense; base of each tergite narrowly covered with microsculpture of fine and dense meshes; rest of tergite with microsculpture of dense and extremely fine transverse waves. Tergite VIII (Fig. 2b) with no special modification. Genital segment of male (Fig. 2c) very similar to that of L. texanus as described by Smetana (1982) and thus probably a generic character as specified by him. Aedeagus (Fig. 2d) similar to that of L. texanus described by Smetana (1982) as a generic character, but differing in the following details: parameres long and narrow, curved laterally and curved distally dorsad; each paramere with a short and acutely pointed basal apophysis, curved distally dorsad; apical portion of median lobe blunt, but having an extension consisting of a split structure narrowed and curved dorsad; distal to the fovea is a sclerotized ridge in form of a letter E turned at 45 o (with short splines pointing basally); the internal sac with unsclerotized internal elongate spines. Slide-mounting of an aedeagus, perhaps with staining, might reveal the internal structures of the internal sac, but this was not attempted due to risk to the unique holotype (and at this stage in the description is not necessary because of the now obvious differences from the only known congener). Male. Length 7.5 mm, described above. Female. Yet unknown. Holotype. Male in UCFC with collection no. UCFC 0 085 911. Label data: USA, FL, Brevard Co. Malabar, Malabar Rd. 23 Sept - 15 Oct. 2000 P.J. Russell, Z. Prusak, S.M. Fullerton / Malabar scrub sand Fire Unit 16 xeric oak scrub Malaise trap / UCFC 0 085 911/. Distribution. Malabar, Brevard Co., Florida, USA. Etymology. Named in honor of Stuart M. Fullerton, the founder and benefactor of the University of Central Florida Insect Collection (UCFC), who was one of the named collectors of the type specimen. Stuart departed this life on 5 April 2014. Diagnostic note. The L. fullertoni adult differs from L. texanus in color, slenderer appearance, head less broadened basally (Fig. 1 vs. 2), and aedeagal structure. The parameral apophyses are short, and acutely pointed, differing greatly from the slender, longer apophyses of L. texanus; the parameres are distinctly longer than the median lobe, as contrasted with equal length in L. texanus. It agrees with Smetana’s generic diagnosis of Lissohypnus in that the distance between the ocular punctures (Fig. 2a) is no more than 2.5 times the distance from the inner margin of the eye (Fig. 1a, 2a), and in a similar complex structure of the aedeagus including a fovea in the distal part of the bulbus (Fig. 2d)., Published as part of Frank, J. H., Kelly, S. L. & Almquist, D. T., 2014, Notes on Diochus Erichson, Lissohypnus Casey, and Oxybleptes Smetana (Coleoptera: Staphylinidae) in Florida, including a description of a new species of Lissohypnus, pp. 1-8 in Insecta Mundi 2014 (382) on pages 4-6, DOI: 10.5281/zenodo.5179513, {"references":["Newton, A. F., M. K. Thayer, J. S. Ashe, and D. S. Chandler. 2001. Staphylinidae Latreille, 1802. p. 272 - 318 In: R. H. Arnett Jr, and M. C. Thomas (eds). American beetles. Volume 1: Archostemata, Myxophaga, Adephaga, Polyphaga: Staphyliniformia. CRC Press; Boca Raton, FL. xv + 442 p.","Blackwelder, R. E. 1943. Monograph of the West Indian beetles of the family Staphylinidae. U. S. National Museum Bulletin 182: i - viii, 1 - 658.","Navarrete-Heredia, J. L., A. F. Newton, M. K. Thayer, J. S. Ashe, and D. S. Chandler. 2002. Guia ilustrada para los generos de Staphylinidae (Coleoptera) de Mexico. Universidad de Guadalajara; Guadalajara, Jalisco. xii + 401 p.","Smetana, A. 1982. Revision of the subfamily Xantholininae of America north of Mexico (Coleoptera: Staphylinidae). Memoirs of the Entomological Society of Canada 120: i - viii, 1 - 289."]}
- Published
- 2014
- Full Text
- View/download PDF
5. Oxybleptes davisi
- Author
-
Frank, J. H., Kelly, S. L., and Almquist, D. T.
- Subjects
Coleoptera ,Insecta ,Arthropoda ,Animalia ,Biodiversity ,Oxybleptes davisi ,Staphylinidae ,Taxonomy ,Oxybleptes - Abstract
Oxybleptes davisi (Notman) 1924: 72 (see Smetana 1982: 254 for redescription) USA, FL, Leon Co., Apalachicola Nat. For. Stand 231 - 10m 2 sand J. R. King Aug 2011 / Pine fltwd; Pitfall 30 o 21’ 34.76” N 84 o 29’ 19.81’ W, (UCFC 0 457 041); as above but Stand 245/13 - control J. R. King Aug 2011 / Pine fltwd; Pitfall 30 o 19’ 02.30” N 84 o 28’ 40.05 W (UCFC 0457 355, 0 457 357, 0 457 358, 0 457 359, 0 457 360, 0 457 361); as above but Stand 245/13 mow J. R. King Aug 2011 / Pine fltwd; Pitfall 30 o 19’ 02.30” N 84 o 28’ 40.05 W (UCFC 0 457 485, 0 457 492, 0 457 499, 0 457 500); as above but Stand 245/13 1m 2 sand J. R. King Aug 2011 / Pine fltwd; Pitfall 30 o 19’ 02.30” N 84 o 28’ 40.05 W (UCFC 0 457 229, 0 457 230, 0 457 231, 0 457 232, 0 457 233, 0 457 234, 0 457 235, 0 457 236); as above but Stand 245/ 13 - 100m 2 sand J. R. King Aug 2011 / Pine fltwd; Pitfall 30 o 19’ 02.30” N 84 o 28’ 40.05 W (UCFC 0 457 262, male dissected); as above but Stand 246W 1m 2 sand J. R. King Aug 2011 Pine fltwd; Pitfall 30 o 18’ 24.39” N 84 o 53.43 W (UCFC 0 456 961, 0 456 962, 0 456 963, 0 456 964, 0 456 965, 0 456 966, 0 456 967, 0 456 969 and 0 457 235) 8 exx. Leon Co. total = 28. USA, FL, Liberty Co., Apal Blffs & Rav Pres, Coll: Preserve Staff, VII-29-2008 / Mxd Hrdwd closed canopy, seepage slope ravine, N 30 o 29’ 42.66” W 84 o 58’ 42.46” 183 ft. Malaise trap/ (UCFC 0 403 480). Liberty Co. total = 1. USA, FL, Orange Co., Orlando, VI-21-1991, longleaf pine saw palmetto, Malaise trap, S.M. Fullerton (UCFC 0 173 709 male dissected, 0 173 908 male dissected), same but VIII-28-1991, longleaf pine - sand pine - turkey oak, (UCFC 0 173 616), same but longleaf pine - sand pine - turkey oak Malaise trap, VII-24-1997 (UCFC 0 173 616), Orange Co., UCF, 28 o 36’ 37” N 81 o 12’ 01” W longleaf pine flatwoods (burn), Malaise traps, M. Carey, S.L. Kelly, S.M. Fullerton V-23-2008 (UCFC 0 466 734), same but VII-20-2012, D.A. Woller, S.M. Fullerton, fluorescent yellow pan traps, oak - sand pine - rosemary scrub (UCFC 0 484 970); Walt Disney World 26 May - 02 June 1998, Z Prusak, S Fullerton, C-4 Stout site, S15,16 T24 S R27 E xeric oak flatwoods, Malaise trap (UCFC 0 173 649, 0 173 6500 and 173 658). Orange Co. total = 9. USA, FL, Wakulla Co., St. Mark’s NWR, 30.13087 oN, 34.30241 oW 4-11 August 2011. D. T. Almquist, FL Natural Areas Inventory survey (gopher tortoise burrow façade trap in sandhill habitat). 5 exx. Same data but 11-18 August 2011. 3 exx. [Details of the trap will be explained in a later paper by DTA]. The specimens will be deposited in FSCA. Wakulla Co. total = 8. The presence of O. davisi in the Florida Panhandle was already suspected (see Frank et al. 2005), but its known distribution was District of Columbia, New Jersey and New York (Smetana 1982). The bigger surprise was to find it also in Orange Co. in central Florida along with O. meridionalis. The new data show that adults of both species may be collected in pitfall traps and that O. meridionalis may be collected in Malaise traps. Adults of O. meridionalis have been collected in all months of the year except February and April, but nothing is known of the immature stages or diet. Smetana (1988) pointed to the smaller, less elongate bulbus of the aedeagus of O. meridionalis, the slightly smaller body size, and the narrower male tergite of the genital segment as differentiating characters from O. davisi. We dissected a male of O davisi from Leon Co., a male from Wakulla Co., and two from Orange Co. and found that the genitalia agree exactly with Smetana’s (1982) description. We add that we find the elytra of O. davisi to be relatively longer and the head, pronotum, and elytra to be relatively glossier. The original collector of O. davisi reported to Notman (1924) that considerable numbers of adults were found running on the tops of several gravestones at Staten Islands, NY on 7 August 1923, that they were running about in daylight, often in circles, and that more were found with the same behavior on 28 September. No mention was made of the kind of stone – whether it had a matte or glossy surface. The earliest collections of O. meridionalis (Frank et al. 2005) were all made in daylight, with the adults found drowning in water or soapy water in artificial containers in circumstances suggesting an attraction to light-colored or glossy surfaces. Later collections with abundant specimens were made by trapping, but in no instance by use of lights at night, supporting the idea of diurnal activity., Published as part of Frank, J. H., Kelly, S. L. & Almquist, D. T., 2014, Notes on Diochus Erichson, Lissohypnus Casey, and Oxybleptes Smetana (Coleoptera: Staphylinidae) in Florida, including a description of a new species of Lissohypnus, pp. 1-8 in Insecta Mundi 2014 (382) on pages 3-4, DOI: 10.5281/zenodo.5179513, {"references":["Smetana, A. 1982. Revision of the subfamily Xantholininae of America north of Mexico (Coleoptera: Staphylinidae). Memoirs of the Entomological Society of Canada 120: i - viii, 1 - 289.","Frank, J. H., J. L. Foltz, and D. T. Almquist. 2005. The female of Oxybleptes meridionalis (Coleoptera: Staphylinidae. Staphylininae) and range extension for Oxybleptes. Florida Entomologist 88: 199 - 200.","Smetana, A. 1988. Revision of the subfamily Xantholininae of America north of Mexico (Coleoptera: Staphylinidae). Supplementum 1. Canadian Entomologist 120: 525 - 558.","Notman, H. 1924. A new xantholinid swarming on gravestones on Staten Island and a new Trogophloeus (Coleoptera: Staphylinidae). Journal of the New York Entomological Society 32: 71 - 72."]}
- Published
- 2014
- Full Text
- View/download PDF
6. Notes on Diochus Erichson, Lissohypnus Casey, and Oxybleptes Smetana (Coleoptera: Staphylinidae) in Florida, including a description of a new species of Lissohypnus
- Author
-
Frank, J. H., Kelly, S. L., Almquist, D. T., Frank, J. H., Kelly, S. L., and Almquist, D. T.
- Abstract
The known range of Oxybleptes meridionalis Smetana (Coleoptera: Staphylinidae) is expanded in Florida, USA, from Indian River and Manatee counties to now include Brevard, Highlands, Orange, Seminole and Volusia. Oxybleptes davisi (Notman) is confi rmed to exist in Florida, with records from Leon, Liberty and Wakulla counties in the Panhandle, and Orange County in central Florida. Lissohypnus texanus Casey is newly reported from Florida. A new species, Lissohypnus fullertoni, is described from Florida. Diochus schaumii Kraatz reverts to this original spelling; its widespread form in Florida is identical to that in the northeastern USA.
- Published
- 2014
7. In search of the mangosteen.
- Author
-
Swain, R.B. and Almquist, D.
- Subjects
- *
BOTANICAL gardens - Abstract
Describes the author's January, 1990 visit to the Lancetilla Botanic Garden (Tela, Honduras) in order to taste the mangosteen fruit grown in the experimental garden. How and why the United Fruit Company founded the garden in 1926; First Director Wilson Popenoe, then 34; The author's guide, John Dickson; Palm collection; Talipots; Description of the mangosteen trees and the mangosteen fruit.
- Published
- 1991
8. Now you see it, now you don't.
- Author
-
Del Tredici, P. and Almquist, D.
- Subjects
- *
FLOWER gardening - Abstract
Discusses combining early and later-blooming flowers in a garden. Hiding dying foliage; Continuous blooming; Suggests combinations.
- Published
- 1990
9. Liability insurance coverage for nontraditional services.
- Author
-
Almquist, D D
- Published
- 1996
- Full Text
- View/download PDF
10. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
- Author
-
Agarwal M, Liu A, Almquist D, Langlais BT, Leventakos K, Yu NY, Manochakian R, and Ernani V
- Subjects
- Humans, Middle Aged, Aged, Retrospective Studies, Etoposide adverse effects, Progression-Free Survival, Small Cell Lung Carcinoma drug therapy, Lung Neoplasms drug therapy, Lung Neoplasms chemically induced
- Abstract
Background: Immune checkpoint inhibitor combined with platinum-etoposide is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The phase 3 clinical trials that led to the approval of chemoimmunotherapy in ES-SCLC excluded patients who had an Eastern Cooperative Group (ECOG) performance status (PS) of 2-3. Therefore, data on the efficacy of chemoimmunotherapy in patients with an ECOG PS of 2-3 are limited., Methods: A retrospective analysis was performed on patients diagnosed with ES-SCLC who received chemoimmunotherapy (atezolizumab or durvalumab) within the Mayo Clinic Health System between January 2016 and January 2021. The objective of this study was to compare the overall survival (OS), progression-free survival (PFS), and best clinical response to therapy in patients with an ECOG PS of 0-1 vs. patients with an ECOG PS of 2-3 who received chemoimmunotherapy for newly diagnosed ES-SCLC., Results: In total, 82 patients were included in the study. The mean ± standard deviation age was 68.1 ± 8.3 years. Of these, 56 patients were identified with an ECOG PS of 0-1, and 26 patients were identified with an ECOG PS of 2-3. The median PFS was similar regardless of ECOG PS (5.8 months [95% CI, 4.3-6.0 months] in the ECOG PS 0-1 group vs. 4.1 months [95% CI, 3.8-6.9 months] in the ECOG PS 2-3; p = .2994). The median OS was also similar regardless of ECOG PS (10.6 months [95% CI, 8.4-13.4 months] in the ECOG PS 0-1 group vs. 9.3 months [95% CI, 4.9-12.8 months]; p = .2718) in the ECOG PS 2-3 group., Conclusions: The study results demonstrated no significant difference in PFS or OS among the ECOG PS 2-3 and ECOG PS 0-1 groups. Therefore, chemoimmunotherapy should be considered for patients who have ES-SCLC with an ECOG PS of 2-3., (© 2023 American Cancer Society.)
- Published
- 2023
- Full Text
- View/download PDF
11. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
- Author
-
Agarwal M, Liu A, Langlais BT, Leventakos K, Yu NY, Almquist D, Manochakian R, and Ernani V
- Subjects
- Adult, Humans, Etoposide, Platinum therapeutic use, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lung Neoplasms drug therapy, Lung Neoplasms etiology, Small Cell Lung Carcinoma drug therapy
- Abstract
Background: Studies demonstrated that chemoimmunotherapy prolongs progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC) and an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1. However, there is little data regarding chemoimmunotherapy in patients with ES-SCLC and an ECOG PS 2 or 3. This study aims to evaluate the benefits of chemoimmunotherapy compared to chemotherapy in the first-line treatment of patients with ES-SCLC and ECOG PS 2 or 3., Materials and Methods: This retrospective study analyzed 46 adults treated at Mayo Clinic between 2017 and 2020 with de novo ES-SCLC and an ECOG PS 2 or 3. Twenty patients received platinum-etoposide and 26 patients received platinum-etoposide and atezolizumab. Progression-free survival (PFS) and Overall survival (OS) were calculated using Kaplan-Meier methods., Results: PFS was longer in the chemoimmunotherapy group compared to the chemotherapy group, 4.1 months (95% confidence interval [CI]: 3.8-6.9) vs. 3.2 months (95% CI: 0.6-4.8), respectively; P = 0.0491. However, there was no statistically significant difference in the OS between the chemoimmunotherapy and chemotherapy group, 9.3 months (95% CI: : 4.9-12.8) vs. 7.6 months (95% CI: 0.6-11.9), respectively; P = .21., Conclusion: Chemoimmunotherapy prolongs PFS compared to chemotherapy in patients with newly diagnosed ES-SCLC and an ECOG PS 2 or 3. No OS difference was observed among the chemoimmunotherapy and chemotherapy groups; nevertheless, this may be attributed due to the small sample size of the study., Competing Interests: Disclosure Dr. Ernani participated in advisory boards for AstraZeneca, Daiichi Sankyo, Pfizer, Bayer, Jazz Pharmaceuticals, Novocure and BioAtla. Dr. Manochakian participated in advisory boards for Guardant Health, AstraZeneca, Novocure, Janssen, Takeda, Turning Points. There are no conflicts of interests for any of the other authors., (Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF
12. The Road Less Traveled: A Guide to Metastatic ROS1 -Rearranged Non-Small-Cell Lung Cancer.
- Author
-
Almquist D and Ernani V
- Subjects
- Gene Rearrangement, Humans, Protein-Tyrosine Kinases genetics, Proto-Oncogene Proteins genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Over the past decade, significant advances have been achieved in the diagnostic testing, treatment, and prognosis of advanced non-small-cell lung cancer (NSCLC). One of the most significant developments was the identification of specific gene alterations that define subsets of NSCLC. In 2007, ROS1 rearrangements were first described and observed in approximately 1%-2% of patients with NSCLC. Currently, crizotinib remains the therapy of choice for advanced ROS1 -rearranged NSCLC without CNS metastases, while entrectinib has emerged as the preferred option for those with CNS metastases. The next-generation inhibitors under development are more potent, have better CNS efficacy, and can overcome important resistance mutations. In this review, we focus on the management of patients with advanced NSCLC harboring a ROS1 rearrangement. We aim to provide insight into the diagnosis, treatment approach, and emerging treatments in this subgroup of NSCLC., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
13. Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia.
- Author
-
Al-Toubah T, Strosberg J, Halfdanarson TR, Oleinikov K, Gross DJ, Haider M, Sonbol MB, Almquist D, and Grozinsky-Glasberg S
- Subjects
- Aged, Antineoplastic Agents therapeutic use, Female, Humans, Hyperplasia, Lung Diseases pathology, Male, Middle Aged, Retrospective Studies, Somatostatin therapeutic use, Treatment Outcome, Lung Diseases complications, Lung Diseases drug therapy, Neuroendocrine Cells pathology, Octreotide therapeutic use, Peptides, Cyclic therapeutic use, Somatostatin analogs & derivatives
- Abstract
Background: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare lung disease associated with proliferation of neuroendocrine cells in the lung and multifocal neuroendocrine tumorlets/tumors. Although usually considered an indolent condition, DIPNECH causes chronic, progressive cough and dyspnea which can adversely impact quality of life. There is very limited information on the treatment of this condition. The objective of this study was to assess changes in symptoms and pulmonary function tests (PFTs) in response to somatostatin analog (SSA) treatment., Methods: Patients with clinical and/or pathologic diagnosis of DIPNECH and chronic respiratory symptoms were treated with SSAs at the H. Lee Moffitt Cancer Center and Research Institute, Hadassah-Hebrew University Medical Center, and Mayo Clinic Cancer Center. Their charts were reviewed to assess changes in symptoms and PFTs., Results: Forty-two patients were identified who had either chronic cough or dyspnea because of proven or suspected DIPNECH and who had received treatment with an SSA. Thirty-three patients experienced symptomatic improvement. Additionally, 14 of 15 patients in whom PFTs were checked were noted to have an improvement in FEV
1 after treatment., Conclusions: SSA treatment can improve chronic respiratory symptoms and PFTs in patients with DIPNECH., (Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
14. Sequential HER2-Targeted Therapy in Salivary Ductal Carcinoma With HER2/neu Overexpression and a Concomitant ERBB2 Mutation.
- Author
-
Almquist D, Umakanthan JM, and Ganti AK
- Published
- 2018
- Full Text
- View/download PDF
15. Preoperative Pulmonary Function Tests (PFTs) and Outcomes from Resected Early Stage Non-small Cell Lung Cancer (NSCLC).
- Author
-
Almquist D, Khanal N, Smith L, and Ganti AK
- Subjects
- Adult, Aged, Carcinoma, Non-Small-Cell Lung mortality, Female, Humans, Kaplan-Meier Estimate, Length of Stay, Lung Neoplasms mortality, Male, Middle Aged, Pneumonectomy adverse effects, Postoperative Complications, Preoperative Care methods, Prognosis, Proportional Hazards Models, Retrospective Studies, Carcinoma, Non-Small-Cell Lung surgery, Lung Neoplasms surgery, Respiratory Function Tests, Treatment Outcome
- Abstract
Background: Preoperative pulmonary function tests (PFTs) predict operative morbidity and mortality after resection in lung cancer. However, the impact of preoperative PFTs on overall outcomes in surgically-resected stage I and II non-small cell lung cancer (NSCLC) has not been well studied., Patients and Methods: This is a retrospective study of 149 patients who underwent surgical resection as first-line treatment for stage I and II NSCLC at a single center between 2003 and 2014. PFTs [forced expiratory volume in 1 sec (FEV1), Diffusing Capacity (DLCO)], both absolute values and percent predicted values were categorized into quartiles. The Kaplan-Meier method and Cox regression analysis were used to determine whether PFTs predicted for overall survival (OS). Logistic regression was used to estimate the risk of postoperative complications and length of stay (LOS) greater than 10 days based on the results of PFTs., Results: The median age of the cohort was 68 years. The cohort was predominantly males (98.6%), current or ex-smokers (98%), with stage I NSCLC (82.76%). The majority of patients underwent a lobectomy (n=121, 81.21%). The predominant tumor histology was adenocarcinoma (n=70, 47%) followed by squamous cell carcinoma (n=61, 41%). The median follow-up of surviving patients was 53.2 months. DLCO was found to be a significant predictor of OS (HR=0.93, 95% CI=0.87-0.99; p=0.03) on univariate analysis. Although PFTs did not predict for postoperative complications, worse PFTs were significant predictors of length of stay >10 days., Conclusion: Preoperative PFTs did not predict for survival from resected early-stage NSCLC, but did predict for prolonged hospital stay following surgery., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
16. Multimodality Therapy for Limited-Stage Small-Cell Lung Cancer.
- Author
-
Almquist D, Mosalpuria K, and Ganti AK
- Subjects
- Disease Management, Drug Resistance, Neoplasm, Humans, Lung Neoplasms mortality, Neoplasm Staging, Premedication, Prognosis, Recurrence, Retreatment, Treatment Outcome, Combined Modality Therapy, Lung Neoplasms pathology, Lung Neoplasms therapy, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma therapy
- Abstract
Limited-stage small-cell lung cancer (SCLC) occurs in only one third of patients with SCLC, but it is potentially curable. Combined-modality therapy (chemotherapy and radiotherapy) has long been the mainstay of therapy for this condition, but more recent data suggest a role for surgery in early-stage disease. Prophylactic cranial irradiation seems to improve outcomes in patients who have responded to initial therapy. This review addresses the practical aspects of staging and treatment of patients with limited-stage SCLC., (Copyright © 2016 by American Society of Clinical Oncology.)
- Published
- 2016
- Full Text
- View/download PDF
17. Liability insurance coverage for nontraditional services.
- Author
-
Almquist DD
- Subjects
- Humans, Societies, Pharmaceutical, United States, Insurance, Liability, Pharmaceutical Services, Pharmacists
- Published
- 1992
18. Report on recent ASHP student activities.
- Author
-
Almquist DD
- Subjects
- Education, Pharmacy, Educational Status, Humans, Societies, Pharmaceutical, Students, Pharmacy, Vocational Guidance
- Published
- 1992
19. Pharmacy: the computer never forgets.
- Author
-
Almquist DD
- Subjects
- Automation, Computers, Data Display, Kansas, Medical Records, Pharmacy Service, Hospital, Electronic Data Processing, Medication Systems, Hospital
- Published
- 1972
20. Manual patient drug profiles as part of a drug distribution system.
- Author
-
Almquist DD
- Subjects
- Electronic Data Processing
- Published
- 1970
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.